The Swiss pharmaceutical association Interpharma said this means that access to vital medicines is becoming increasingly difficult.
The benchmarking study conducted by the pharmaceutical industry and the Swiss Agency for Therapeutic Products, Swissmedic, reveals that companies are submitting their applications later in Switzerland compared to Europe, and that the duration of the review process has also increased, Interpharma announced on Wednesday.
More
More
What’s behind Switzerland’s push for drug-pricing secrecy?
This content was published on
The Swiss parliament is considering measures on drug pricing that are drawing the ire of some health experts.
On average, a drug is approved in Switzerland 249 days later than by the EMA, which represents a 48% increase compared to the previous year. Companies submitted their applications for authorisation to Swissmedic 244 days later than to the EMA.
Interpharma attributes this to the poor framework conditions in Switzerland, which have caused the Swiss market to receive progressively less priority.
Translated from German by DeepL/sp
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles.
If you want to know more about how we work, have a look here, if you want to learn more about how we use technology, click here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
Popular Stories
More
Life & Aging
Zurich: how the world capital of housing shortages is tackling the problem
Is your place of origin, your Heimatort, important to you?
Every Swiss citizen has a Heimatort, a place of origin, but many have never visited theirs. What’s your relationship with your Heimatort? What does it mean to you?
In Switzerland more people are being referred to electrical therapies or psychedelic-assisted psychotherapy. Are there similar approaches where you live?
Pope was a person full of respect: Swiss president
This content was published on
Swiss president Karin Keller-Sutter, who is attending the funeral of Pope Francis, says the pontiff was always full of respect.
Ex-sect member sentenced in Zurich for sexual abuse
This content was published on
Zurich District Court has sentenced a former member of the globally active sect "Children of God" to a partial prison sentence.
SNB chairman does not rule out slowdown in Swiss growth
This content was published on
Martin Schlegel, chairman of the Swiss National Bank (SNB), does not rule out a weakening of the Swiss economy in light of the tariff dispute.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Secret discounts leave patients at drugmakers’ mercy
This content was published on
A University of Zurich study has found that using confidential discounts on drugs does little to make them available faster and more affordable.
How drug prices are negotiated in Switzerland and beyond
This content was published on
Switzerland's pharmaceutical sector supplies drugs worldwide, but not all countries receive them with the same price tag. Here's why.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.